Immune cells and genetic engineering technology

The cancer research community underwent a sea change in 2013, with encouraging results from clinical trials of cancer immunotherapy, in which treatments target the body's immune system rather than directly targeting tumors. This new form of treatment prompts T cells and other immune cells to fight the tumor, which is why cancer immunotherapy took the top spot in 2013's Top 10 Tech Breakthroughs list.

Longyao Biotechnology integrates domestic and foreign core technologies in this field, creates immune cell technology with CAR-T and T-DC1s as the core, enhances the killing ability of NK cell technology and CIK technology, improves the health of patients and prolongs life.